{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:11:02Z","timestamp":1785352262984,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10461-024-04597-4","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:47:24Z","timestamp":1736383644000},"page":"1228-1234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB\u2009+\u2009RPV Regimen: A Prospective Observational Study"],"prefix":"10.1007","volume":"29","author":[{"given":"V.","family":"Iannone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-8346","authenticated-orcid":false,"given":"F.","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ciccullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. F.","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Baldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Borghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Torti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"4597_CR1","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.jval.2021.04.070","volume":"24","author":"J Flamm","year":"2021","unstructured":"Flamm J, Garris C, D\u2019Amico R, et al. Pb4 patient perspectives on implementation of a long-acting Injectable antiretroviral therapy regimen in HIV US Healthcare settings: final month 12 results from the CUSTOMIZE study. Value Health. 2021;24:S13. https:\/\/doi.org\/10.1016\/j.jval.2021.04.070.","journal-title":"Value Health"},{"key":"4597_CR2","doi-asserted-by":"publisher","first-page":"e070666","DOI":"10.1136\/bmjopen-2022-070666","volume":"13","author":"HZ Farooq","year":"2023","unstructured":"Farooq HZ, Apea V, Kasadha B, et al. Study protocol: the ILANA study - exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritized people and older people living with HIV in the UK - a qualitative multiphase longitudinal study design. BMJ Open. 2023;13:e070666. https:\/\/doi.org\/10.1136\/bmjopen-2022-070666.","journal-title":"BMJ Open"},{"key":"4597_CR3","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","volume":"10","author":"MN Ramgopal","year":"2023","unstructured":"Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10:e566\u201377.","journal-title":"Lancet HIV"},{"key":"4597_CR4","doi-asserted-by":"publisher","unstructured":"Delle Donne V, Massaroni V, Lombardi F, et al. The association between stigma and wellbeing in an Italian cohort of PWH: the role of social support and personal factors. Int J STD AIDS. 2023;9564624231213115. https:\/\/doi.org\/10.1177\/09564624231213115.","DOI":"10.1177\/09564624231213115"},{"key":"4597_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.7326\/M23-0788","volume":"176","author":"M Gandhi","year":"2023","unstructured":"Gandhi M, Hickey M, Imbert E, et al. Demonstration project of long-acting antiretroviral therapy in a Diverse Population of people with HIV. Ann Intern Med. 2023;176:969\u201374.","journal-title":"Ann Intern Med"},{"key":"4597_CR6","doi-asserted-by":"publisher","first-page":"ofad390","DOI":"10.1093\/ofid\/ofad390","volume":"10","author":"W Chen","year":"2023","unstructured":"Chen W, Gandhi M, Sax PE, et al. Projected benefits of long-acting antiretroviral therapy in Nonsuppressed People with Human Immunodeficiency Virus Experiencing Adherence barriers. Open Forum Infect Dis. 2023;10:ofad390. https:\/\/doi.org\/10.1093\/ofid\/ofad390.","journal-title":"Open Forum Infect Dis"},{"key":"4597_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/hiv.13370","volume":"24","author":"R D\u2019Amico","year":"2023","unstructured":"D\u2019Amico R, Cenoz Gomis S, Moodley R, et al. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy. HIV Med. 2023;24:202\u201311.","journal-title":"HIV Med"},{"key":"4597_CR8","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","volume":"8","author":"H Jaeger","year":"2021","unstructured":"Jaeger H, Overton ET, Richmond G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021;8:e679\u201389.","journal-title":"Lancet HIV"},{"key":"4597_CR9","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1016\/S2352-3018(21)00184-3","volume":"8","author":"C Orkin","year":"2021","unstructured":"Orkin C, Bernal Morell E, Tan DHS, et al. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021;8:e668\u201378.","journal-title":"Lancet HIV"},{"key":"4597_CR10","unstructured":"European AIDS, Clinical Society. EACS Guidelines. Available at: https:\/\/www.eacsociety.org\/media\/guidelines-12.0. Final.pdf. (October 2023, date last accessed)."},{"key":"4597_CR11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"4597_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jviromet.2014.02.020","volume":"202","author":"M Jones","year":"2014","unstructured":"Jones M, Williams J, G\u00e4rtner K, et al. Low copy target detection by Droplet Digital PCR through application of a novel open access bioinformatic pipeline, \u2018definetherain\u2019. J Virol Methods. 2014;202:46\u201353.","journal-title":"J Virol Methods"},{"key":"4597_CR13","doi-asserted-by":"crossref","unstructured":"Hsu RK, Sension M, Fusco JS et al. Real-world use of long-acting cabotegravir\u2009+\u2009rilpivirine in people with HIV with detectable viral loads at initiation: findings from the OPERA cohort. Abstract presented at IDWeek 2023; October 11\u201315, 2023; Boston, MA.","DOI":"10.1093\/ofid\/ofad500.059"},{"key":"4597_CR14","doi-asserted-by":"crossref","unstructured":"Ciccullo A, Iannone V, Lombardi F et al. Real-life experience of long-acting cabotegravir-rilpivirine combination in a person living with HIV with detectable viremia: a case report. AIDS Res Hum Retroviruses. 2024.","DOI":"10.1089\/aid.2023.0057"},{"issue":"4","key":"4597_CR15","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s10461-022-03854-8","volume":"27","author":"A Dusina","year":"2023","unstructured":"Dusina A, Lombardi F, Tamburrini E, Onorati F, Petrucci M, Di Giambenedetto S. Home Care Assistance: has Covid-19 had an impact on the Complex Management of HIV patients? AIDS Behav. 2023;27(4):1173\u201381. https:\/\/doi.org\/10.1007\/s10461-022-03854-8. Epub 2022 Sep 26.","journal-title":"AIDS Behav"},{"key":"4597_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003862","author":"EP Hyle","year":"2024","unstructured":"Hyle EP, Wattananimitgul N, Mukerji SS, et al. Age-associated dementia among older people aging with HIV in the US: a modeling study. AIDS. 2024. https:\/\/doi.org\/10.1097\/QAD.0000000000003862.","journal-title":"AIDS"},{"key":"4597_CR17","doi-asserted-by":"publisher","unstructured":"Zdanowicz MM, Valdes B, Salani D. Management of HIV in the older adults: Clinical and public health challenge. Public Health Nurs. 2024. https:\/\/doi.org\/10.1111\/phn.13288. Epub ahead of print. PMID: 38323718.","DOI":"10.1111\/phn.13288"},{"key":"4597_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-023-00590-4","volume":"21","author":"E Adachi","year":"2024","unstructured":"Adachi E, Saito M, Otani A, et al. Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine. AIDS Res Ther. 2024;21:1.","journal-title":"AIDS Res Ther"},{"key":"4597_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel. JAMA. 2023;329:63\u201384.","journal-title":"JAMA"},{"key":"4597_CR20","unstructured":"Gandhi M, Salazar J, Hickey MD et al. High virologic suppression rates on long-acting ART in a safety-net clinic population. 2023. Available at: https:\/\/www.croiconference.org\/abstract\/high-virologic-suppression-rates-on-long-acting-art-in-a-safety-net-clinic-population\/. Accessed 2 May 2023."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04597-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-024-04597-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04597-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:53:45Z","timestamp":1744275225000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-024-04597-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["4597"],"URL":"https:\/\/doi.org\/10.1007\/s10461-024-04597-4","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"18 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.C. received support for travel to meetings from ViiV Healthcare. A.B. received a speakers\u2019 honoraria from ViiV Healthcare, and fees for attending advisory boards from Janssen-Cilag, S.D.G. was a paid consultant or member of the advisory boards for Gilead Sciences, ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme and Bristol-Myers Squibb. None of the other authors have anything to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol and informed consent documents were reviewed and approved by our local Ethics Committee (Fondazione Policlinico Universitario A. Gemelli IRCCS) (7768\/16).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Individual consent was obtained before participation of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}